A divided panel of the U.S. Court of Appeals for the Ninth Circuit sided with the Trump administration on Friday, reviving a Department of Justice subpoena targeting a telemedicine clinic accused of prescribing sex-change drugs to children. The 2-1 ruling reversed a lower court order that had blocked the subpoena and sent the case back for further proceedings, the first time a federal appeals court has upheld one of the DOJ’s investigative demands against a pediatric gender-transition provider.
The decision landed in a legal landscape where federal courts have repeatedly stalled the administration’s effort to probe clinics and doctors involved in prescribing puberty blockers and cross-sex hormones to minors. That pattern made Friday’s ruling a notable break, and a signal that at least one appellate panel believes the executive branch can direct its enforcement apparatus toward what the court itself called “an unsettled scientific debate.”
The case centers on QueerDoc, a Washington state-based telehealth provider. The DOJ subpoena demands the clinic’s personnel files, billing documents, communications with drug manufacturers, and records of patients who were prescribed puberty blockers or cross-sex hormones, as Breitbart News reported. QueerDoc, represented by the ACLU, argued the subpoena was too broad, too burdensome, and driven by political animus rather than legitimate law enforcement.
A lower court agreed with the clinic and halted the subpoena. The Ninth Circuit majority disagreed.
Judge Carlos Bea, a George W. Bush appointee, wrote the majority opinion. Judge Daniel Bress, a Trump nominee, joined him. The dissenting judge was not identified in available reporting. Bea’s opinion addressed head-on the argument that the administration’s open opposition to pediatric sex-change procedures made the subpoena illegitimate:
“Every President has law enforcement priorities, just as every President has signature policies (often, the former are components of the latter).”
The majority held that a president may direct the DOJ to exercise its statutory authority in line with his broader policy goals, and that policy opposition to sex-change procedures for children does not, by itself, constitute bad faith. The AP reported the panel found the lower court erred in blocking the subpoena on those grounds.
The court also acknowledged that the long-term risks of sex-change drugs for minors remain “uncertain” and characterized the broader medical question as “an unsettled scientific debate.” That framing matters. It undercuts the claim, common among progressive advocacy groups and some medical organizations, that pediatric gender transition is settled science requiring no further scrutiny.
QueerDoc is not the only target. The DOJ announced last year that it had issued more than 20 subpoenas to doctors and clinics allegedly providing sex-change drugs and surgeries to minors. The investigation covers potential “healthcare fraud, false statements, and more,” though the full scope of the probe remains unclear.
The administration’s legal authority flows from a pair of Trump executive orders. One reaffirms the biological reality of male and female and eschews the concept of “gender identity.” The other seeks to end federal funding of sex-change procedures for minors and directs the DOJ to “prioritize investigations” into violations of a drug safety law by “any entity that may be misleading the public about long-term side effects of chemical and surgical mutilation.” The Trump administration recently moved to cut Medicaid and CHIP funding for gender-transition procedures on children, reinforcing the policy direction.
Brett Shumate, DOJ Assistant Attorney General for the Civil Division, framed the ruling in blunt terms. The Washington Examiner reported his statement: “The trans medical industry is not above the law.”
That line captures the core dispute. The administration contends that clinics like QueerDoc may be misleading patients, many of them minors, about the risks of the drugs they prescribe. The clinics and their legal advocates say the subpoenas are politically motivated fishing expeditions designed to chill access to care.
ACLU attorney Adrien Leavitt, who represents QueerDoc, signaled the fight is far from over:
“We’re ready to continue defending one of the most fundamental principles of healthcare: every patient’s right to confidential medical care.”
That framing, confidential medical care, is doing heavy lifting. The subpoena seeks patient records alongside billing and personnel documents. Privacy concerns are real. But invoking patient confidentiality to shield a clinic from a federal investigation into potential fraud and misleading practices is a different proposition than protecting an individual’s medical file from a nosy neighbor.
The case now returns to the lower court. Whether QueerDoc can mount additional challenges before being forced to comply remains an open question. The remand means the subpoena is not yet enforceable, but the appellate ruling strips away the broadest shield the clinic had: the argument that the administration’s policy stance alone disqualified the investigation.
The broader legal fight over pediatric sex-change procedures continues to roil courts at every level. Federal judges in multiple jurisdictions have blocked or stalled the DOJ’s subpoena campaign. The Ninth Circuit ruling is the first appellate crack in that wall.
The Ninth Circuit’s characterization of the medical evidence as “uncertain” aligns with what major medical institutions have acknowledged, even as advocacy groups push for unrestricted access. The Mayo Clinic has noted that puberty blockers carry long-term risks to bone growth, bone density, and growth spurts. The World Professional Association for Transgender Health, often cited as the leading authority in the field, has advocated for removing age limits on sex-change procedures entirely.
One detail from WPATH’s own internal discussions underscores the problem the DOJ is probing. An endocrinologist associated with the organization described discussing long-term infertility with a 14-year-old patient as “like talking to a blank wall.” If the professionals administering these treatments acknowledge that minors cannot meaningfully grasp the consequences, the question of informed consent, and whether clinics are adequately conveying risks, becomes more than a policy debate. It becomes a potential legal issue.
Courts across the country have grappled with where to draw lines. In Kansas, a judge blocked a state ban on gender-transition drugs for minors, prompting an appeal from the state attorney general. These cases share a common thread: the tension between an expanding medical industry and growing public concern about irreversible interventions on children.
The Trump DOJ’s subpoena campaign has faced sustained judicial resistance. Federal courts have blocked or delayed compliance in multiple cases, often citing concerns about the administration’s motives. The Ninth Circuit, historically the most liberal federal appeals court in the country, was not the venue where most observers expected the administration to notch its first win.
That it happened here, with a Bush appointee writing the opinion and a Trump appointee joining, does not diminish the legal reasoning. The majority’s logic is straightforward: every president sets enforcement priorities, and directing the DOJ to investigate potential violations of drug safety law is within the executive’s authority. The alternative, that courts can quash subpoenas whenever they disagree with the president’s policy views, would set a precedent far more dangerous than the one the ACLU fears.
The Supreme Court has recently delivered wins for the administration on other fronts, reinforcing the principle that executive enforcement discretion is broad. Whether the high court eventually weighs in on the pediatric gender-transition subpoenas remains to be seen.
Several questions hang over the case. No charges or findings have been announced from the broader investigation involving more than 20 subpoenas. The specific drug safety law cited in the executive order has not been publicly identified in detail. And the identity and reasoning of the lone dissenting judge on the Ninth Circuit panel remain unknown.
Strip away the legal maneuvering and the political noise, and the core question is simple: Should the federal government be allowed to investigate whether clinics are telling children and their parents the truth about drugs that can cause infertility, bone damage, and other irreversible effects?
The ACLU says the subpoena threatens patient privacy. The DOJ says it is investigating potential fraud. The Ninth Circuit says the investigation can proceed, at least past the first hurdle.
For the children prescribed these drugs, the stakes are not abstract. They are permanent.
When the medical establishment itself admits that a 14-year-old cannot understand what infertility means, and advocacy groups push to remove all age limits anyway, the federal government is not overreaching by asking to see the paperwork. It is doing the minimum.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.
By signing up, you agree to receive newsletters and promotional content from American Frontline News and selected publications in the American Digest Media Network, operated with Patriot Mom Digest LLC, and you accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.